Il 12 23 Inhibitor denied as not medically necessary by Cigna?

Cigna requires prior authorization for ustekinumab (Stelara and biosimilars) and the same criteria apply across the IL-12/23 inhibitor class. The SC formulation is covered for Crohn's disease (CD), plaque psoriasis (PsO), psoriatic arthritis (PsA), and ulcerative colitis (UC), while the IV formulation is covered for CD and UC. Prior authorization is required for benefit coverage of ustekinumab intravenous, and approval is recommended only for those who meet the Criteria and Dosing for the listed indications. Initial therapy is approved for 6 months if criteria are met; continuation/re-authorization is approved for 1 year if the patient has been established on the drug for at least 3–6 months and continues to respond. The medication must be prescribed by or in consultation with a specialist in the condition being treated, and certain approvals are limited to 30 days when that is an adequate duration. Concurrent use with another biologic or with a targeted synthetic oral small molecule drug used for an inflammatory condition is not allowed because combination therapy is generally not recommended due to a potentially higher rate of adverse events and lack of controlled clinical data supporting additive efficacy , though conventional synthetic DMARDs (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) are not excluded. Through the Preferred Specialty Management program, the patient is required to meet the standard PA criteria and to try ALL of the Preferred Products prior to approval of a Non-Preferred Product. Pediatric dosing for PsA/PsO follows weight-based limits: pediatric patients ≥12 years weighing 60–100 kg receive 45 mg SC at Week 0, Week 4, then Q12W; those weighing <60 kg receive 90 mg SC at Week 0, Week 4, then Q12W.

- For step-therapy denials in IBD: AGA Clinical Guidelines on the Management of Moderate-to-Severe Ulcerative Colitis and Crohn's Disease support ustekinumab as a first-line biologic option, particularly in TNF-naïve patients; the UNITI-1, UNITI-2, IM-UNITI, and UNIFI pivotal trials demonstrated efficacy that does not require failure of every preferred product if medically inappropriate. - For psoriasis/PsA step-therapy denials: AAD-NPF Joint Guidelines (2019) and ACR/NPF PsA guidelines list ustekinumab as a recommended biologic; cite PHOENIX 1 & 2 (PsO) and PSUMMIT 1 & 2 (PsA) showing durable PASI 75 and ACR20 responses, supporting medical necessity when TNF inhibitors are contraindicated (e.g., demyelinating disease, CHF, latent TB risk). - For combination-therapy denials: cite that conventional synthetic DMARDs (methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) are NOT excluded from concurrent use , so co-prescription with MTX should not trigger denial. - For specialist-prescriber denials: provide attestation from a rheumatologist/GI/derm or documented consult note, satisfying the requirement that the medication be prescribed by or in consultation with a specialist . - For non-FDA indication denials in AS/nr-axSpA: cite the TOPAS open-label study which showed 65% of patients (95% CI: 41%, 85%) achieved an ASAS40 response at Week 24 , supporting off-label medical necessity when ACR/SPARTAN-recommended TNFi and IL-17 options have failed or are contraindicated. - For continuation/reauthorization denials: submit objective response data (PASI improvement, Mayo/CDAI reduction, HBI, joint counts) showing the patient meets the established-therapy criterion of established on the requested drug for at least 3 months . - For non-preferred biosimilar denials on Employer/IFP plans: request a formulary exception citing significant allergy/intolerance to inactive ingredients in preferred products, per documentation supporting that formulation differences in inactive ingredients would result in a significant allergy .

## Why Cigna Denies IL-12/23 Inhibitors on Medical Necessity Grounds

Cigna's medical-necessity reviews for IL-12/23 inhibitors (a class that includes biologics approved for conditions such as moderate-to-severe plaque psoriasis, psoriatic arthritis, and certain inflammatory bowel diseases) typically focus on whether the clinical record demonstrates that conventional or less-intensive therapies have been tried and failed, that the patient's condition meets a defined severity threshold, and that the prescribing clinician has documented a clear rationale for this specific mechanism of action. When those elements are missing or insufficiently documented, Cigna issues a medical-necessity denial.

This type of denial is almost always appealable, because payers must follow a structured review process and must explain, in writing, exactly which criteria were not met.

## Your Federal Appeal Rights

• Internal appeal: Under ACA §2719 and ERISA §503, you have the right to a full-and-fair internal appeal. Submit a written appeal with supporting documentation within the timeframe stated on your denial letter (commonly 180 days for ERISA plans, but verify your specific plan).
• External review: If the internal appeal is denied, you may escalate to an independent external reviewer. The ACA external-review window is generally within approximately four months of the final internal denial. An accredited Independent Review Organization (IRO) — not employed by Cigna — will evaluate the case.
• Expedited review: If a standard timeline would seriously jeopardize your health, you may request expedited internal and external review, often with a decision in 72 hours or fewer.

## What to Gather Before You File

1. Diagnosis confirmation: Specialist notes, pathology or biopsy records, or other objective findings that establish the diagnosis and its severity according to your physician's assessment. 2. Severity documentation: Chart entries, validated scoring tools used by your clinician, photographs (for skin conditions), or procedure notes that reflect disease burden over time. 3. Prior-treatment history: A dated log of every therapy previously tried — generic and brand names, start and stop dates, doses attempted, and the specific reason each was discontinued (inadequate response, intolerance, contraindication per your treating physician). 4. Prescriber medical-necessity letter: A detailed letter from the ordering physician explaining why the IL-12/23 inhibitor is necessary for this patient, referencing the applicable guideline organization (e.g., the relevant AAD, ACR, or AGA guideline) without relying on Cigna's document to make the clinical argument. 5. FDA-approved prescribing information: Pull the current FDA label for the specific IL-12/23 inhibitor prescribed. Confirm that your documented clinical situation aligns with the labeled indication.

## Criteria-Mapping Structure

Cigna's published coverage policy lists specific requirements. Obtain Cigna's current medical coverage policy for the drug from Cigna's website or your denial letter. Then create a point-by-point response:

| Cigna Requirement | Evidence in Your Chart | |---|---| | Confirmed diagnosis of [condition] | [Cite specialist note date and finding] | | Documented failure of required prior therapies | [List each therapy with dates and outcome] | | Severity meets defined threshold | [Cite clinician's documented assessment] | | Prescribed by appropriate specialist | [Cite prescriber credentials and role] |

Answer each line with a specific chart reference. Unanswered lines are the most common reason appeals are denied a second time.